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ABSTRACT The objective of the present study was to
estimate the preventive effect of folic acid for structural birth
defects (i.e. congenital abnormalities [CAs]) in the offspring of
pregnant women with diabetes mellitus type 1 (DM-1). The
occurrence of medically recorded DM-1 in pregnant women
who had malformed fetuses/newborns (cases) and delivered
healthy babies (controls) with or without folic acid supplemen-
tation was compared in the population-based Hungarian
Case-Control Surveillance System of Congenital Abnormali-
ties. The case group included 22 843 offspring, and there were
79 (0.35%) pregnant women with DM-1, while the control
group comprised of 38 151 newborns, and 88 (0.23%) had
mothers with DM-1. Case mothers with DM-1 associated with a
higher risk of total rate of CAs in their offspring (OR with 95%
CI: 1.5, 1.1–2.0) compared to the total rate of CAs in the off-
spring of non-diabetic case mothers. This higher risk can be
explained by four specific types/groups of CAs: isolated renal
a/dysgenesis; obstructive CA of the urinary tract; cardiovascu-
lar CAs; and multiple CAs, namely caudal dysplasia sequence.
However, there was no higher rate of total CAs in the children
of pregnant women with DM-1 after folic acid supplementation;
in addition, neural-tube defect and renal a/dysgenesis did not
occur. However, this benefit cannot be explained by the CA
reduction effect of folic acid during the critical period of major
CAs. In conclusion, there was a certain reduction in maternal
teratogenic effect of DM-1 after folic acid supplementation
during pregnancy, but the explanation of this effect requires
further study.
Key Words: congenital abnormality, diabetes mellitus type 1, folic
acid, population-based case-control study, pregnancy
INTRODUCTION
Maternal diabetes mellitus (DM) during pregnancy associates with
a higher risk of certain structural birth defects (i.e. congenital
abnormalities [CAs]) in the offspring (Moore 2004). The spectrum
of DM-related isolated CAs (Molsted-Pedersen et al. 1964; Becerra
et al. 1990; Nielsen et al. 2005) includes neural-tube defects
(Milunsky et al. 1982), cardiovascular CAs, particularly transposi-
tion of great vessels, double outlet right ventricle, and common
truncus (Ferencz et al. 1990; Loffredo et al. 2001), kidney CA
(renal a/dysgenesis), obstructive CAs of the urinary tract, congeni-
tal limb deficiency (mainly a/dysplasia of femoral head), CAs of
spines (Rusnak and Driscoll 1965; Martinez-Frias et al. 1998;
Greene 1999; Sheffield et al. 2002) and a specific multiple CA, the
so-called caudal dysplasia sequence (Kucera et al. 1965; Passarge
and Lenz 1966).
Three main types of DM are differentiated, such as type 1
(DM-1), with the previous term juvenile-onset DM or insulin
dependent DM (IDDM); type 2, with the previous term adult-
onset DM or non-insulin dependent DM (NIDDM); and gesta-
tional DM. Our previous study showed a 1.5-fold higher risk of
CAs in the offspring of pregnant women with DM-1 (Bánhidy
et al. 2010). However, the risk of CAs in the offspring of pregnant
women with overt DM prior to conception was four to eight times
higher in the previous studies (Moore 2004); thus, our previous
study may reflect recent progress in the specific medical care of
diabetic pregnant women (Bánhidy et al. 2010). The objective of
this study was to check whether recently introduced periconcep-
tional folic acid supplementation may contribute to the reduction
of CAs in the offspring of pregnant women with DM-1, because
folic acid diminished diabetes-induced embryotoxicity in rats
(Gareskog et al. 2006). The population-based dataset of the Hun-
garian Case-Control Surveillance of Congenital Abnormalities
(HCCSCA), 1980–1996 (Czeizel et al. 2001) seemed to be appro-
priate to reply to this question.
MATERIALS AND METHODS
Subjects: cases and controls
Cases were selected from the dataset of the Hungarian Congenital
Abnormality Registry (HCAR), 1980–1996 (Czeizel 1997) for the
HCCSCA as described previously (Czeizel et al. 2001; Bánhidy
et al. 2010).
Two main categories of cases with CAs were differentiated:
isolated (only one organ is affected) and multiple (concurrence of
two or more CAs in the same person affecting at least two different
organ systems) (Czeizel 2009b). The total (birth + fetal) prevalence
of cases with CA diagnosed from the second trimester of pregnancy
through the age of one year was 35 per 1000 informative offspring
(live-born infants, stillborn fetuses and electively terminated mal-
formed fetuses) in the HCAR, 1980–1996 (Czeizel 1997), and
about 90% of major CAs was recorded in the HCAR during the 17
years of the study period (Czeizel et al. 1993).
Controls were indentified and selected from the National Birth
Registry of the Central Statistical Office for the HCCSCA. Controls
were defined as newborn infants without CA. In general, two con-
trols were matched to every case according to sex, birth week, and
district of parents’ residence.
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Collection of maternal, particularly exposure data
Prospective and medically recorded data
Mothers were asked to send us the prenatal maternity logbook and
other medical records, particularly discharge summaries in an
explanatory letter. Prenatal care was mandatory for pregnant
women in Hungary (if a pregnant woman did not visit prenatal care
clinic, she did not receive a maternity grant and leave); thus, nearly
100% of pregnant women visited prenatal care clinics, on an
average of seven times during each pregnancy. The first visit was
between the 6th and 12th gestational weeks when obstetricians
recorded all pregnancy complications, maternal diseases and related
drug prescriptions in the prenatal maternity logbook. The protocol
of Hungarian prenatal care includes checking the blood glucose
level of pregnant women.
Retrospective maternal information
A structured questionnaire, along with a list of drugs, pregnancy
supplements and diseases, plus a printed informed consent form
were also mailed to the mothers immediately after the selection of
cases and controls. Mothers were asked to fill in the questionnaire
after reading a list of medicinal products and diseases as a memory
aid and provide a signature for the informed consent form.
The mean  SD time elapsed between birth or pregnancy termi-
nation and return of the ‘information package’ (questionnaire,
logbook, etc.) in our prepaid envelope was 3.5 1.2 and 5.2 2.9
months in the case and control groups, respectively,
Supplementary data collection
Regional nurses were asked to visit all non-respondent case mothers
at home to help mothers to fill in the questionnaire, evaluate avail-
able medical records and obtain data regarding the lifestyle
(smoking and drinking habits, and elicit drug use during the study
pregnancy) through a cross-interview of mothers and their male
partners or relatives if they were living with them. Regional nurses
could visit only 200 non-respondent and 600 respondent control
mothers as part of two validation studies (Czeizel et al. 2003;
Czeizel and Vargha 2004) because the committee on ethics consid-
ered that it would be disturbing to the parents of all healthy controls
to be visited. Regional nurses used the same method as in non-
respondent case mothers.
The necessary information was available in 96.3% of cases
(84.4% from reply to the mailing, 11.9% from the nurse visit) and
in 83.0% of the controls (81.3% from reply, 1.7% from visit).
Gestational time was calculated from the first day of the last
menstrual period. The critical period of most major CAs is in the
second and/or third gestational month (Czeizel 2008; Czeizel et al.
2008).
Related drug treatments and use of folic acid or folic acid con-
taining multivitamin supplements were also evaluated (Czeizel
2009a). Only one type of 3 mg folic acid tablet was available in
Hungary during the study period. Among other potential confound-
ing factors, maternal age, birth order, and marital and employment
statuses as indicators of socio-economic status (Puho et al. 2004)
were evaluated.
Diagnostic criteria of DM-1
DM-1 was recorded in the prenatal maternity logbooks in all preg-
nant women in the HCCSCA, and all pregnant women with DM-1
were treated with insulin, because pregnant women with DM-1 had
low to absent insulin level and acute or subacute appearance of
symptoms of DM-1, thus, they needed insulin treatment for life.
The onset of DM-1 is predominantly under 30 years of age with a
peak of 9 years in general in non-obese patients who are prone to
ketosis (Moore 2004).
Pregnant women with specified diagnosis of DM-2 or unspeci-
fied DM diagnosis before the conception of the study pregnancy
without insulin treatment were excluded from the study. The diag-
nosis of gestational DM was based on the recognition of DM during
the study pregnancy; these pregnant women were also excluded
from the study.
Statistical analysis
SAS version 8.02 (SAS Institute, Cary, NC, USA) was used for
statistical analyses of data. First, the main maternal variables were
evaluated in case and control pregnant women using Student’s t-test
for quantitative while c2 was used test for categorical variables at
the comparison of pregnant women with DM-1 and without DM as
reference. The prevalence of other maternal diseases, drug intake
and pregnancy supplement, particularly folic acid and folic acid
containing multivitamins during pregnancy, in addition to preg-
nancy complications were compared between the group of case and
control mothers with DM-1 using odds ratios (OR) with 95% con-
fidence intervals (CI). We compared the occurrence of DM-1 during
the study pregnancy in specific CA groups of cases and in all
matched controls, and adjusted OR with 95% CI were evaluated in
conditional logistic regression models. Confounding variables were
analyzed by comparing the OR for DM-1 in the models with and
without inclusion of the potential confounding variables. Maternal
age (<20 years, 20–29 years, and 30 years or more), birth order (first
delivery or one or more previous deliveries), employment status,
and maternal hypertension (yes/no) were included in the model as
potential confounders. Finally, the distribution of specified
CA-groups was evaluated in the offspring of pregnant women with
DM-1 according to the folic acid/multivitamin supplementation
during the study pregnancy.
RESULTS
The case group included 22 843 offspring with CA, and there were
79 (0.35%) pregnant women with DM-1. The control group com-
prised 38 151 newborns without CA, and 88 (0.23%) had mothers
with DM-1 during the study pregnancy.
Of 79 diabetic case mothers, 40 (50.6%), while of 88 diabetic
control mothers, 54 (61.4%) had folic acid supplementation
during the study pregnancy (OR with 95% CI: 0.65, 0.33–1.25).
The use of folic acid was lower in non-diabetic case (49.3%) and
control (54.4%) mothers. Of 40 diabetic case mothers, 35
(87.5%), while of 54 diabetic control mothers, 49 (90.7%) had
medically recorded folic acid supplementation in the prenatal
maternity logbooks. These proportions were much higher than in
non-diabetic pregnant women (about 67%). However, of 40 case
mothers, only 23 (57.5%), while of 54 control mothers, only 36
(66.7%) had folic acid supplementation during the periconcep-
tional period, including the critical period (i.e. the second and/or
third gestational months) of major CAs. Our validation study
showed that 89% and 11% of diabetic women used one or two
folic acid tablets, respectively; therefore, the estimated daily dose
was 3.3 mg. There was no difference in case and control diabetic
mothers in this aspect. The distribution of folic acid users was
different in non-diabetic pregnant women: 22%, 69% and 9% of
women used one, two and three folic acid tablets, respectively;
therefore, the estimated daily dose was 5.6 mg. Folic acid con-
taining micronutrient combinations, so-called multivitamins were
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also planned to be evaluated in the study, however, these multi-
vitamins were not used by 79 case diabetic women while of 88
control diabetic mothers, 7 (8.0%) used multivitamins, therefore
diabetic pregnant women with multivitamin supplementation were
excluded from this analysis.
The characteristics of pregnant women with DM-1, as well as
with or without folic acid supplementation are shown in Table 1.
The mean maternal age was higher in the DM-1 groups than in the
reference sample, with a somewhat higher mean birth order. The
distribution of employment status indicated a better socioeconomic
status of pregnant women with DM-1.
Folic acid supplemented diabetic mothers were somewhat
younger with lower mean birth order than diabetic mothers without
folic acid use. The proportion of professional women was three
times higher in diabetic case mothers with folic acid use than in
diabetic case mothers without folic acid supplementation; however,
a similar difference was not seen in the subgroups of diabetic
control mothers.
Among other maternal diseases, only essential hypertension
showed a higher prevalence in case and control diabetic pregnant
women (16.5% and 18.2%) than in non-diabetic pregnant women
(6.9%). Thus, the use of antihypertensive drugs, beyond insulin,
showed an obvious difference between diabetic and non-diabetic
pregnant women.
The estimation of risk for different CAs in the offspring of
pregnant women with DM-1 compared to the rate of CAs in the
offspring of non-diabetic pregnant women is shown in Table 2.
Pregnant women with DM-1 had a higher risk of total rate of CAs
in their offspring (OR with 95% CI: 1.5, 1.1–2.0), explained mainly
by three isolated CA groups: isolated renal a/dysgenesis, obstruc-
tive CA of the urinary tract (including 2 cases with cystic dysplasia),
cardiovascular CA (including 12 cases with ventricular septal
defect, but the second most common CA was transposition of great
vessels in 5 cases) and by the group of multiple CAs.
However, the major objective of the study was to check
whether folic acid supplementation during pregnancy can reduce
the risk of DM-related CA; therefore, pregnant women with
DM-1 were differentiated into two subgroups: with or without
folic acid supplementation during the study pregnancy (Table 2).
The total rate of CAs was not higher in the offspring of diabetic
pregnant women with folic acid supplementation during preg-
nancy (OR with 95% CI: 1.1, 0.7–1.7). There was no offspring
with neural-tube defect and renal a/dysgenesis in the folic acid
supplemented subgroups, and only one case was affected with
obstructive CAs of the urinary tract and cleft lip with or without
cleft palate. The risk of cardiovascular CAs and multiple CAs has
remained higher in the subgroups of diabetic pregnant women
with folic acid supplementation. However, the total rate of CAs
was significantly higher in the offspring of diabetic pregnant
women without folic acid supplementation (OR with 95%
CI: 1.7, 1.1–2.7), explained mainly by the higher rate of renal
a/dysgenesis, obstructive CAs of urinary tract, cleft lip with or
without cleft palate and cardiovascular CAs.
Finally, it would be necessary to evaluate the effect of folic acid
according to the time of supplementation because the critical
period of major CAs is during the second and/or third gestational
month; therefore, a beneficial preventive effect of folic acid can be
expected only with the use of folic acid during this time window.
Table 3 shows the effect of folic acid supplementation (i) during
the second and/or third gestational month (nearly all pregnant
women continued folic acid use later in their pregnancy) (ii) in
4–9 months (late onset) and (iii) no use of folic acid. Unfortu-
nately, the numbers are too low for appropriate statistical analysis.
Neural-tube defects and renal a/dysplasia did not occur in the off-
spring of mothers with folic acid supplementation; therefore, there
was no chance to differentiate these cases according to the time of
folic acid use. Of 2 cases with cleft palate and of 4 cases with
obstructive CA of urinary tract, none occurred in the children of
diabetic pregnant women with folic acid supplementation during
the second and/or third gestational months. However, of 4 cases
with cleft lip with or without cleft palate, 1 was recorded in the
child of diabetic pregnant woman with folic acid supplementation
in the critical period of this CA. Obviously folic acid had no
preventive effect for isolated cardiovascular and other isolated
CAs, as well as multiple CAs during its use in the second and/or
third gestational months.
DISCUSSION
The maternal teratogenic effect of DM, particularly DM-1 is well-
known due to the poor metabolic control in pregnant women
because there is no higher risk of CA in the children of diabetic
fathers and normoglycemic pregnant women. In our previous study
a higher rate of isolated renal a/dysgenesis, obstructive CAs of
urinary tract and cardiovascular CAs, particularly transposition of
great vessels and the specific multiple CA (caudal dysplasia
sequence) was found in the offspring of pregnant women with
DM-1 (Bánhidy et al. 2010). However, the lower risk (1.5-fold)
found in this study than was expected (4 fold) based on previous
reports suggested the beneficial effect of the recent progress in the
special medical care of diabetic pregnant women.
The periconceptional low (0.4 mg) doses of folic acid (Berry
et al. 1999) or folic acid (0.8 mg) containing multivitamin
(Czeizel and Dudas 1992) supplementation can reduce signifi-
cantly the first occurrence of neural-tube defects. In addition, as
the Hungarian randomized controlled and cohort controlled trials
showed, periconceptional folic acid-containing multivitamin
supplementation was able to reduce the occurrence of cardiovas-
cular (particularly conotruncal) and urinary tract (mainly obstruc-
tive) CAs (Czeizel 1996; Czeizel et al. 2004). However, this
primary preventive method was not able to reduce the occurrence
of multiple CAs (Czeizel and Medvecki 2003). The evaluation of
population-based case-control dataset in Hungary showed that
high doses of folic acid reduced the birth prevalence of isolated
cardiovascular CAs (Czeizel et al. 1996) and orofacial clefts
(Czeizel et al. 1999), but not the occurrence of multiple CAs
(Czeizel et al. 2006). Thus, the objective of this study was
whether the recent use of folic acid in diabetic pregnant women
has contributed to the diminished risk of CAs in pregnant women
with DM-1.
However, the reply to question expressed in the title of this paper
is controversial. On the one hand the first approach of the study
showed the beneficial effect of folic acid for the reduction of
DM-related CAs in the offspring of pregnant women with DM-1.
There was a lower risk of total CAs, in addition neural-tube defects
and renal a/dysgenesis did not occur in the offspring of diabetic
pregnant women after folic acid use during pregnancy. However,
when the effect of folic acid supplementation was evaluated during
the second and/or third gestational months (i.e. the critical period of
major CAs), our hypothesis was not confirmed, partly due to the
limited number of cases with CA. Obviously there was no reduction
in the rate of caudal dysplasia sequence in agreement with the lack
of reduction of multiple CAs after the periconceptional use of folic
acid-containing multivitamin or high dose of folic acid (Czeizel and
Medvecki 2003, Czeizel et al. 2006).
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Thus the seemingly beneficial effect of folic acid for the reduction
of CAs in the offspring of pregnant women with DM-1 may be an
indirect association explained by the higher socioeconomic status
and better medical care of these pregnant women. The latter was
indicated by their higher use of folic acid supplementation (particu-
larly in diabetic control women) compared to non-diabetic pregnant
women. Obviously other unevaluated confounders should also be
considered. Nevertheless it is worth checking the possible preventive
effect of folic acid for DM-related CAs in other larger observational
studies or intervention trials because folic acid may be a promising
contributor to the further progress of the medical care of diabetic
pregnant women to reduce the risk of adverse birth outcomes
An important purpose of the Hungarian pre/periconceptional
service including folic acid containing multivitamin supplementa-
tion introduced in 1984 was to provide a special care for diabetic
pregnant women (Czeizel 1999). Of about 25 thousand women
between 1984 and 2009, 144 pregnant women were diabetic and a
folic acid-containing multivitamin (Elevit Prenatal; Roche/Bayer,
Leverkusen, Germany) during the periconceptional period was able
to reduce the maternal teratogenic effect of diabetes mellitus.
The strengths of the HCCSCA are the population-based and large
dataset, including 167 pregnant women with prospectively and
medically recorded DM-1 in an ethnically homogeneous Hungarian
(Caucasian) population. Additional strengths are the differentiation
of DM-1 from other types of DM, the matching of cases to controls
without CAs; the knowledge of potential confounders. Finally the
diagnosis of medically notified CAs was checked in the HCAR and
later modified, if necessary, on the basis of recent medical exami-
nation within the HCCSCA.
The weakness of our study is the 0.23% prevalence of DM-1 that
indicates an underascertainment of pregnant women with DM-1 in
our study sample and the limited number of cases with different
CAs avoided the more detailed analysis of the putative preventive
effect of folic acid during the critical period of major CAs.
In conclusion our study was not able to prove that the lower risk
of DM-related CAs in the offspring of diabetic pregnant women
with folic acid supplementation can be explained by the direct CA
preventive effect of folic acid, but this possible beneficial effect
needs studies to improve further the medical care of diabetic
pregnant women.
REFERENCES
Bánhidy F, Ács N, Puho HE, Czeizel AE (2010) Congenital abnormalities
in the offspring of pregnant women with type 1, type 2 and gestational
diabetes mellitus – a population-based case-control study. Congenit
Anom 50: 115–121.
Becerra JE, Khoury MJ, Cordero JF, Erickson JD (1990) Diabetes mellitus
during pregnancy and the risk for specific birth defects: a population-
based case-control study. Pediatrics 85: 1–9.
Berry RJ, Li Z, Erickson JD, Wang H et al. (1999) Prevention of neural tube
defects with folic acid in China-US Collaborative Project for Neural Tube
Defect Prevention. N Engl J Med 341: 1485–1490.
Czeizel AE (1996) Reduction of urinary tract and cardiovascular defects by
periconceptional multivitamin supplementation. Am J Med Genet 62:
179–183.
Czeizel AE (1997) The first 25 years of the Hungarian Congenital Abnor-
mality Registry. Teratology 55: 299–305.
Czeizel AE (1999) Ten years experience in periconceptional care. Eur J
Obstet Gynecol Reprod Biol 84: 43–49.
Czeizel AE (2008) Specified critical period of different congenital abnor-
malities: a new approach for human teratological studies. Congenit Anom
48: 103–109.
Czeizel AE (2009a) Periconceptional folic acid and multivitamin supple-
mentation for the prevention of neural tube defects and other congenital
abnormalities. Birth Defects Res (Part A) 85: 260–268.
Czeizel AE (2009b) The estimation of human teratogenic/fetotoxic risk of
exposures to drugs on the basis of Hungarian experience: a critical evalu-
ation of clinical and epidemiological models of human teratology. Expert
Opin Drug Saf INFORMA Pharm Sci 8: 283–303.
Czeizel AE, Dudas I (1992) Prevention of the first occurrence of neural-tube
defects by periconceptional vitamin supplementation. N Engl J Med 327:
1832–1835.
Czeizel AE, Medvecki E (2003) No difference in the occurrence of multi-
malformed offspring after periconceptional multivitamin supplementa-
tion. Obstet Gynecol 102: 1255–1261.
Czeizel AE, Vargha P (2004) Periconceptional folic acid/multivitamin
supplementation and twin pregnancy. Am J Obstet Gynecol 191: 790–794.
Czeizel AE, Dobo M, Vargha P (2004) Hungarian cohort-controlled trial of
periconceptional multivitamin supplementation shows reduction in
certain congenital abnormalities. Birth Defects Res (Part A) 70: 853–861.
Czeizel AE, Into˝dy Z, Modell B (1993) What proportion of congenital
abnormalities can be prevented? Br Med J 306: 499–503.
Czeizel AE, Petik D, Vargha P (2003) Validation studies of drug exposures
in pregnant women. Pharm Drug Saf 12: 409–416.
Table 3 Number (%) of cases born to pregnant women with diabetes mellitus type 1 (DM-1) according to the time-window of folic acid
supplementation during the study pregnancy
Study group
No folic acid
Folic acid use
Total1–3 months 4–9 months
No. % No. % No. % No.
Controls 34 38.6 36 40.9 18 20.5 88
Isolated CAs
Neural-tube defects 3 100.0 0 0.0 0 0.0 3
Cleft lip with or without cleft palate 4 80.0 1 20.0 0 0.0 5
Cleft palate 2 67.7 0 0.0 1 33.3 3
Renal a/dysgenesis 3 100.0 0 0.0 0 0.0 3
Obstructive CAs of urinary tract 3 75.5 0 0.0 1 25.0 4
Cardiovascular CAs 12 46.2 9 34.6 5 19.2 26
Other isolated CAs 10 38.5 10 38.5 6 23.1 26
Multiple CAs 2 22.2 3 33.3 4 44.4 9
Total 39 49.4 23 29.1 17 21.5 79
Folic acid and diabetic birth defects 85
© 2011 The Authors
Congenital Anomalies © 2011 Japanese Teratology Society
Czeizel AE, Puho HE, Ács N, Bánhidy F (2008) Use of specified critical
periods of different congenital abnormalities instead of the first trimester
concept. Birth Defects Res (Part A) 82: 139–146.
Czeizel AE, Puhó E, Bánhidy F (2006) No association between periconcep-
tional multivitamin supplementation and risk of multiple congenital
abnormalities. A population-based case-control study. Am J Med Genet
Part A 140A: 2469–2477.
Czeizel AE, Rockenbauer M, Siffel C, Varga E (2001) Description and
mission evaluation of the Hungarian Case-Control Surveillance of
Congenital Abnormalities, 1980–1996. Teratology 63: 176–185.
Czeizel AE, Timás L, Sárközi A (1999) Dose-dependent effect of folic acid
on the prevention of orofacial clefts. Pediatrics 104: e66.
Czeizel AE, Tóth M, Rockenbauer M (1996) Population-based case-control
study of folic acid supplementation during pregnancy. Teratology 53:
345–351.
Ferencz C, Rubin JN, McCarter RJ, Clark EB (1990) Maternal diabetes and
cardiovascular malformations: predominance of double outlet right ven-
tricle and truncus arteriosus. Teratology 41: 319–326.
Gareskog M, Ericksson UJ, Wentzel P (2006) Combined supplementation of
folic acid and vitamin E diminishes diabetes-induced embryotoxicity in
rats. Birth Defects Res (Part A) 76: 483–490.
Greene MF (1999) Spontaneous abortions and major malformations in
women with diabetes mellitus. Semin Reprod Endocrinol 17: 127–136.
Kucera J, Lenz W, Maier W (1965) Missbildungen der Beine und der
kaudalen Wirbelsaule bei Kindern diabetischer Mütter. Dtsch Med
Wochenschr 90: 901–905.
Loffredo CA, Wilson PD, Ferencz C (2001) Maternal diabetes: an indepen-
dent risk factor for major cardiovascular malformations with increased
mortality of affected infants. Teratology 64: 98–106.
Martinez-Frias NL, Bemejo E, Rodriguez-Pinilla E et al. (1998) Epidemio-
logical analysis of outcomes of pregnancy in gestational diabetic mothers.
Am J Med Genet 78: 140–145.
Milunsky A, Alpert E, Kitzmiller JL et al. (1982) Prenatal diagnosis of
neural tube defects. The importance of serum alfa-fetoprotein in diabetic
pregnant women. Am J Obstet Gynecol 142: 1030–1032.
Molsted-Pedersen L, Tygstrup I, Pedersen J (1964) Congenital malforma-
tions in newborn infants of diabetic women. Correlation with maternal
diabetes vascular complications. Lancet 1: 1124–1126.
Moore TR (2004) Diabetes in pregnancy. In: Creasy RK, Resnik R, Iams JS,
eds. Maternal-Fetal Medicine, 5th edn. Saunders, Philadelphia, pp.
1023–1061.
Nielsen GL, Norgard B, Puho E et al. (2005) Risk of specific congenital
abnormalities in offspring of women with diabetes. Diabet Med 22:
693–696.
Passarge E, Lenz W (1966) Syndrome of caudal regression in infants of
diabetic mothers: observations of further cases. Pediatrics 37: 672–675.
Puho HE, Métneki J, Czeizel AE (2004) Maternal employment status and
isolated orofacial clefts in Hungary. Cent Eur J Publ Health 13: 144–148.
Rusnak SL, Driscoll SG (1965) Congenital spinal anomalies in infants of
diabetic mothers. Pediatrics 35: 989–995.
Sheffield JS, Butler-Koster EL, Casey BM et al. (2002) Maternal diabetes
mellitus and infants malformations. Obstet Gynecol 100: 925–930.
86 F. Bánhidy et al.
© 2011 The Authors
Congenital Anomalies © 2011 Japanese Teratology Society
